{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:57:24Z","timestamp":1791489444653,"version":"4.3.4"},"reference-count":86,"publisher":"The Endocrine Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,11,1]]},"abstract":"<jats:p>No specific treatment is available for ovarian hyperstimulation syndrome (OHSS), the most important complication in infertile women treated with gonadotropins. OHSS is caused by increased vascular permeability (VP) through ovarian hypersecretion of vascular endothelial growth factor (VEGF)-activating VEGF receptor 2 (VEGFR-2). We previously demonstrated in an OHSS rodent model that increased VP was prevented by inactivating VEGFR-2 with a receptor antagonist (SU5416). However, due to its toxicity (thromboembolism) and disruption of VEGFR-2-dependent angiogenic processes critical for pregnancy, this kind of compound cannot be used clinically to prevent OHSS. Dopamine receptor 2 (Dp-r2) agonists, used in the treatment of human hyperprolactinemia including pregnancy, inhibit VEGFR-2-dependent VP and angiogenesis when administered at high doses in animal cancer models. To test whether VEGFR-2-dependent VP and angiogenesis could be segregated in a dose-dependent fashion with the Dp-r2 agonist cabergoline, a well-established OHSS rat model supplemented with prolactin was used. A 100 \u03bcg\/kg low-dose Dp-r2 agonist cabergoline reversed VEGFR-2-dependent VP without affecting luteal angiogenesis through partial inhibition of ovarian VEGFR-2 phosphorylation levels. No luteolytic effects (serum progesterone levels and luteal apoptosis unaffected) were observed. Cabergoline administration also did not affect VEGF\/VEGFR-2 ovarian mRNA levels. Results in the animal model and the safe clinical profile of Dp-r2 agonists encouraged us to administer cabergoline to oocyte donors at high risk for developing the syndrome. Prophylactic administration of cabergoline (5\u201310 \u03bcg\/kg\u00b7d) decreased the occurrence of OHSS from 65% (controls) to 25% (treatment). Therefore, a specific, safe treatment for OHSS is now available.<\/jats:p>","DOI":"10.1210\/en.2006-0657","type":"journal-article","created":{"date-parts":[[2006,8,11]],"date-time":"2006-08-11T00:25:34Z","timestamp":1155255934000},"page":"5400-5411","source":"Crossref","is-referenced-by-count":128,"title":["Low-Dose Dopamine Agonist Administration Blocks Vascular Endothelial Growth Factor (VEGF)-Mediated Vascular Hyperpermeability without Altering VEGF Receptor 2-Dependent Luteal Angiogenesis in a Rat Ovarian Hyperstimulation Model"],"prefix":"10.1210","volume":"147","author":[{"given":"Raul","family":"Gomez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Gonzalez-Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf C.","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edurne","family":"Novella-Maestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Alonso-Muriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Sanchez-Criado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Remohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pellicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071613344987000_R1","first-page":"1489","article-title":"Circulatory dysfunction in asymptomatic in vitro fertilization patients. Relationship with hyperestrogenemia and activity of endogenous vasodilators","volume":"83","author":"Manau","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613344987000_R2","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/oxfordjournals.humrep.a137488","article-title":"Modern management of ovarian hyperstimulation syndrome","volume":"6","author":"Rizk","year":"1991","journal-title":"Hum Reprod"},{"key":"2020071613344987000_R3","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMp038106","article-title":"The pathogenesis of the ovarian hyperstimulation syndrome","volume":"349","author":"Kaiser","year":"2003","journal-title":"N Engl J Med"},{"key":"2020071613344987000_R4","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0015-0282(16)57987-4","article-title":"Characteristics of blood hemostatic markers in a patient with ovarian hyperstimulation syndrome who actually developed thromboembolism","volume":"64","author":"Kodama","year":"1995","journal-title":"Fertil Steril"},{"key":"2020071613344987000_R5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/00313029500169273","article-title":"A fatal case of ovarian hyperstimulation syndrome with cerebral infarction","volume":"27","author":"Cluroe","year":"1995","journal-title":"Pathology"},{"key":"2020071613344987000_R6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1440-1827.2000.01082.x","article-title":"An autopsy case of ovarian hyperstimulation syndrome with massive pulmonary edema and pleural effusion","volume":"50","author":"Semba","year":"2000","journal-title":"Pathol Int"},{"key":"2020071613344987000_R7","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/humrep\/deg116","article-title":"Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome. An aggressive, but perhaps life-saving procedure","volume":"18","author":"Amarin","year":"2003","journal-title":"Hum Reprod"},{"key":"2020071613344987000_R8","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/oxfordjournals.humrep.a138115","article-title":"Prevention and treatment of ovarian hyperstimulation","volume":"8","author":"Schenker","year":"1993","journal-title":"Hum Reprod"},{"key":"2020071613344987000_R9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/humupd\/dmg018","article-title":"Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures","volume":"9","author":"Aboulghar","year":"2003","journal-title":"Hum Reprod Update"},{"key":"2020071613344987000_R10","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1210\/en.2002-220204","article-title":"Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade","volume":"143","author":"Gomez","year":"2002","journal-title":"Endocrinology"},{"key":"2020071613344987000_R11","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1126\/science.6823562","article-title":"Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid","volume":"219","author":"Senger","year":"1983","journal-title":"Science"},{"key":"2020071613344987000_R12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(94)93001-5","article-title":"Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome","volume":"344","author":"McClure","year":"1994","journal-title":"Lancet"},{"key":"2020071613344987000_R13","first-page":"1967","article-title":"Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor\/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome","volume":"80","author":"Neulen","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613344987000_R14","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1172\/JCI4814","article-title":"Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome","volume":"102","author":"Levin","year":"1998","journal-title":"J Clin Invest"},{"key":"2020071613344987000_R15","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1210\/jcem.87.7.8651","article-title":"Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor","volume":"87","author":"Wang","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613344987000_R16","first-page":"1723","article-title":"Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro","volume":"77","author":"Yan","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613344987000_R17","first-page":"353","article-title":"Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation","volume":"81","author":"Gordon","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613344987000_R18","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1210\/jcem.84.10.6025","article-title":"The vascular endothelial growth factor\/fms-like tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy","volume":"84","author":"Otani","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613344987000_R19","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3109\/09513599709152564","article-title":"Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary","volume":"11","author":"Yamamoto","year":"1997","journal-title":"Gynecol Endocrinol"},{"key":"2020071613344987000_R20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0015-0282(98)00484-1","article-title":"The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1\u03b2, interleukin-6, and vascular endothelial growth factor","volume":"71","author":"Pellicer","year":"1999","journal-title":"Fertil Steril"},{"key":"2020071613344987000_R21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0015-0282(98)00447-6","article-title":"Serum vascular endothelial growth factor concentrations in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome","volume":"71","author":"Agrawal","year":"1999","journal-title":"Fertil Steril"},{"key":"2020071613344987000_R22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0015-0282(97)81908-5","article-title":"Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome","volume":"67","author":"Abramov","year":"1997","journal-title":"Fertil Steril"},{"key":"2020071613344987000_R23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.2479987","article-title":"Vascular permeability factor, an endothelial cell mitogen related to PDGF","volume":"246","author":"Keck","year":"1989","journal-title":"Science"},{"key":"2020071613344987000_R24","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"key":"2020071613344987000_R25","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1210\/endo-127-2-965","article-title":"Vascular endothelial growth factor is expressed in rat corpus luteum","volume":"127","author":"Phillips","year":"1990","journal-title":"Endocrinology"},{"key":"2020071613344987000_R26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1537-1891(03)00011-9","article-title":"Regulation of vascular permeability by vascular endothelial growth factors","volume":"39","author":"Bates","year":"2002","journal-title":"Vascul Pharmacol"},{"key":"2020071613344987000_R27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1046\/j.1469-7580.2002.00066.x","article-title":"Regulation of microvascular permeability by vascular endothelial growth factors","volume":"200","author":"Bates","year":"2002","journal-title":"J Anat"},{"key":"2020071613344987000_R28","doi-asserted-by":"crossref","first-page":"26988","DOI":"10.1016\/S0021-9258(18)47116-5","article-title":"Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor","volume":"269","author":"Waltenberger","year":"1994","journal-title":"J Biol Chem"},{"key":"2020071613344987000_R29","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1074\/jbc.M002016200","article-title":"Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants","volume":"276","author":"Gille","year":"2001","journal-title":"J Biol Chem"},{"key":"2020071613344987000_R30","first-page":"99","article-title":"SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1\/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types","volume":"59","author":"Fong","year":"1999","journal-title":"Cancer Res"},{"key":"2020071613344987000_R31","first-page":"1648","article-title":"Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma","volume":"9","author":"Kuenen","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2020071613344987000_R32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1517\/14712598.3.2.263","article-title":"VEGF blocking therapy in the treatment of cancer","volume":"3","author":"Glade-Bender","year":"2003","journal-title":"Expert Opin Biol Ther"},{"key":"2020071613344987000_R33","first-page":"3377","article-title":"Luteal angiogenesis: prevention and intervention by treatment with vascular endothelial growth factor trap(A40)","volume":"86","author":"Wulff","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613344987000_R34","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/en.2004-0765","article-title":"The vascular endothelial growth factor (VEGF)\/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent","volume":"146","author":"Pauli","year":"2005","journal-title":"Endocrinology"},{"key":"2020071613344987000_R35","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1172\/JCI200318740","article-title":"Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotropin-dependent follicle development","volume":"112","author":"Zimmermann","year":"2003","journal-title":"J Clin Invest"},{"key":"2020071613344987000_R36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/mvre.2001.2312","article-title":"Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea","volume":"62","author":"Zimmermann","year":"2001","journal-title":"Microvasc Res"},{"key":"2020071613344987000_R37","first-page":"768","article-title":"Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey","volume":"86","author":"Zimmermann","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613344987000_R38","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1095\/biolreprod.102.006700","article-title":"Inhibition of vascular endothelial growth factor\/vascular permeability factor action blocks estrogen-induced uterine edema and implantation in rodents","volume":"67","author":"Rockwell","year":"2002","journal-title":"Biol Reprod"},{"key":"2020071613344987000_R39","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1530\/rep.0.1250337","article-title":"Effect of angiogenesis inhibitors on oestrogen-mediated endometrial endothelial cell proliferation in the ovariectomized mouse","volume":"125","author":"Heryanto","year":"2003","journal-title":"Reproduction"},{"key":"2020071613344987000_R40","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000180041","article-title":"Effects of chronic bromocriptine treatment of an estrone-induced, prolactin-secreting rat pituitary adenoma","volume":"21","author":"Eljarmak","year":"1985","journal-title":"Horm Res"},{"key":"2020071613344987000_R41","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1023\/A:1018862309440","article-title":"Alteration of dopamine D2 receptors in human malignant stomach tissue","volume":"42","author":"Basu","year":"1997","journal-title":"Dig Dis Sci"},{"key":"2020071613344987000_R42","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1158\/0008-5472.CAN-04-1600","article-title":"Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor\/vascular endothelial growth factor-mediated angiogenesis","volume":"64","author":"Basu","year":"2004","journal-title":"Cancer Res"},{"key":"2020071613344987000_R43","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/87895","article-title":"The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor\/vascular endothelial growth factor","volume":"7","author":"Basu","year":"2001","journal-title":"Nat Med"},{"key":"2020071613344987000_R44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000122476","article-title":"Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats","volume":"20","author":"Mueller","year":"1976","journal-title":"Neuroendocrinology"},{"key":"2020071613344987000_R45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1152\/ajplegacy.1954.180.1.47","article-title":"Disturbance of hormone balance in the female rat by a single injection of ergotoxine ethanesulphonate","volume":"180","author":"Shelesnyak","year":"1955","journal-title":"Am J Physiol"},{"key":"2020071613344987000_R46","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1210\/jcem-47-2-290","article-title":"Normal pregnancies after treatment of hyperprolactinemia with bromoergocryptine, despite suspected pituitary tumors","volume":"47","author":"Mornex","year":"1978","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613344987000_R47","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1023\/A:1015319007880","article-title":"Successful treatment of a large macroprolactinoma with cabergoline during pregnancy","volume":"4","author":"Liu","year":"2001","journal-title":"Pituitary"},{"key":"2020071613344987000_R48","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/BF03348017","article-title":"Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy","volume":"20","author":"Ciccarelli","year":"1997","journal-title":"J Endocrinol Invest"},{"key":"2020071613344987000_R49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1210\/jcem-48-1-9","article-title":"A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments","volume":"48","author":"Bigazzi","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613344987000_R50","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0890-6238(96)00063-9","article-title":"Pregnancy outcome after treatment with the ergot derivative, cabergoline","volume":"10","author":"Robert","year":"1996","journal-title":"Reprod Toxicol"},{"key":"2020071613344987000_R51","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/humrep\/12.8.1629","article-title":"Role of progesterone in capillary permeability in hyperstimulated rats","volume":"12","author":"Ujioka","year":"1997","journal-title":"Hum Reprod"},{"key":"2020071613344987000_R52","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1095\/biolreprod.102.010801","article-title":"Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability","volume":"68","author":"Gomez","year":"2003","journal-title":"Biol Reprod"},{"key":"2020071613344987000_R53","first-page":"449","article-title":"Increased capillary permeability mediated by a dengue virus-induced lymphokine","volume":"69","author":"Khanna","year":"1990","journal-title":"Immunology"},{"key":"2020071613344987000_R54","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nm0398-336","article-title":"Vascular endothelial growth factor is essential for corpus luteum angiogenesis","volume":"4","author":"Ferrara","year":"1998","journal-title":"Nat Med"},{"key":"2020071613344987000_R55","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1210\/endo-85-3-393","article-title":"Regulation of lipid metabolism and progesterone production in rat corpora lutea and ovarian interstitial elements by prolactin and luteinizing hormone","volume":"85","author":"Armstrong","year":"1969","journal-title":"Endocrinology"},{"key":"2020071613344987000_R56","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0015-0282(16)46753-1","article-title":"Prolactin in the evaluation of luteal phase in infertility","volume":"39","author":"Vanrell","year":"1983","journal-title":"Fertil Steril"},{"key":"2020071613344987000_R57","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7827-1-12","article-title":"Effects of deletion of the prolactin receptor on ovarian gene expression","volume":"1","author":"Grosdemouge","year":"2003","journal-title":"Reprod Biol Endocrinol"},{"key":"2020071613344987000_R58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0005-2760(69)90140-4","article-title":"Induction of 20\u03b1-hydroxysteroid dehydrogenase in rat corpora lutea by pharmacological blockade of pituitary prolactin secretion","volume":"187","author":"Lamprecht","year":"1969","journal-title":"Biochim Biophys Acta"},{"key":"2020071613344987000_R59","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy","volume":"86","author":"Di Sarno","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613344987000_R60","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2169\/internalmedicine.40.857","article-title":"Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients","volume":"40","author":"Sabuncu","year":"2001","journal-title":"Intern Med"},{"key":"2020071613344987000_R61","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2165\/00002018-199614040-00003","article-title":"A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation","volume":"14","author":"Webster","year":"1996","journal-title":"Drug Saf"},{"key":"2020071613344987000_R62","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1095\/biolreprod55.6.1284","article-title":"RU486-treated rats show endocrine and morphological responses to therapies analogous to responses of women with polycystic ovary syndrome treated with similar therapies","volume":"55","author":"Ruiz","year":"1996","journal-title":"Biol Reprod"},{"key":"2020071613344987000_R63","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/sj.onc.1201047","article-title":"The 230 kDa mature form of KDR\/Flk-1 (VEGF receptor-2) activates the PLC-\u03b3 pathway and partially induces mitotic signals in NIH3T3 fibroblasts","volume":"14","author":"Takahashi","year":"1997","journal-title":"Oncogene"},{"key":"2020071613344987000_R64","doi-asserted-by":"crossref","first-page":"27081","DOI":"10.1074\/jbc.M110544200","article-title":"The presence of a single tyrosine residue at the carboxyl domain of vascular endothelial growth factor receptor-2\/FLK-1 regulates its autophosphorylation and activation of signaling molecules","volume":"277","author":"Meyer","year":"2002","journal-title":"J Biol Chem"},{"key":"2020071613344987000_R65","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/sj.onc.1207034","article-title":"Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2\/p38","volume":"23","author":"Lamalice","year":"2004","journal-title":"Oncogene"},{"key":"2020071613344987000_R66","doi-asserted-by":"crossref","first-page":"16788","DOI":"10.1021\/bi981291f","article-title":"Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis","volume":"37","author":"Parast","year":"1998","journal-title":"Biochemistry"},{"key":"2020071613344987000_R67","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/humrep\/13.8.2068","article-title":"Elevated concentrations of angiogenin in serum and ascitic fluid from patients with severe ovarian hyperstimulation syndrome","volume":"13","author":"Aboulghar","year":"1998","journal-title":"Hum Reprod"},{"key":"2020071613344987000_R68","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1210\/jcem.82.2.3727","article-title":"The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome","volume":"82","author":"Fulghesu","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613344987000_R69","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/0002-9378(74)90673-5","article-title":"Antihistamine blockade of the ovarian hyperstimulation syndrome","volume":"118","author":"Knox","year":"1974","journal-title":"Am J Obstet Gynecol"},{"key":"2020071613344987000_R70","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/oxfordjournals.humrep.a019403","article-title":"Ovarian hyperstimulation syndrome: pre-ovulatory serum concentrations of interleukin-6, interleukin-1 receptor antagonist and tumour necrosis factor-\u03b1 cannot predict its occurrence","volume":"11","author":"Loret de Mola","year":"1996","journal-title":"Hum Reprod"},{"key":"2020071613344987000_R71","first-page":"1428","article-title":"Expression of endothelin-1 gene and protein in human granulosa cells","volume":"81","author":"Magini","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613344987000_R72","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0015-0282(16)59290-5","article-title":"Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome","volume":"48","author":"Navot","year":"1987","journal-title":"Fertil Steril"},{"key":"2020071613344987000_R73","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejogrb.2005.01.009","article-title":"Cabergoline: a safe, easy, cheap, and effective drug for prevention\/treatment of ovarian hyperstimulation syndrome?","volume":"122","author":"Manno","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"Suppl 3","key":"2020071613344987000_R74","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0015-0282(03)01918-6","article-title":"Tyroxine hydroxylase (TH) downregulation in hyperstimulated ovaries reveals the dopamine agonist bromocriptine (Br2) as an effective and specific method to block increased vascular permeability (VP) in OHSS (Abstract O-113)","volume":"80","author":"Gomez","year":"2003","journal-title":"Fertil Steril"},{"key":"2020071613344987000_R75","doi-asserted-by":"crossref","first-page":"H1554","DOI":"10.1152\/ajpheart.00272.2004","article-title":"Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells","volume":"287","author":"Sarkar","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2020071613344987000_R76","doi-asserted-by":"crossref","first-page":"32714","DOI":"10.1074\/jbc.M103130200","article-title":"Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor\/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively","volume":"276","author":"Zeng","year":"2001","journal-title":"J Biol Chem"},{"key":"2020071613344987000_R77","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1006\/bbrc.1997.7719","article-title":"Interactions of FLT-1 and KDR with phospholipase C \u03b3: identification of the phosphotyrosine binding sites","volume":"240","author":"Cunningham","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071613344987000_R78","first-page":"i96","article-title":"The dopamine agonist Cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients","volume":"21","author":"Alvarez","year":"2006","journal-title":"Hum Reprod"},{"key":"2020071613344987000_R79","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1210\/jcem-63-4-941","article-title":"Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients","volume":"63","author":"Ferrari","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613344987000_R80","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2125.1987.tb03072.x","article-title":"Selective and extremely long inhibition of prolactin release in man by 1-ethyl-3-(3\u2032-dimethylaminopropyl)-3-(6\u2032-allylergoline-8\u2032-\u03b2-carbonyl)-urea-diphosphate (FCE 21336)","volume":"23","author":"Pontiroli","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"2020071613344987000_R81","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/jcem.82.3.3822","article-title":"Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613344987000_R82","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1172\/JCI8218","article-title":"VEGF antagonism reduces edema formation and tissue damage after ischemia\/reperfusion injury in the mouse brain","volume":"104","author":"van Bruggen","year":"1999","journal-title":"J Clin Invest"},{"key":"2020071613344987000_R83","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1172\/JCI200420702","article-title":"Src blockade stabilizes a Flk\/cadherin complex, reducing edema and tissue injury following myocardial infarction","volume":"113","author":"Weis","year":"2004","journal-title":"J Clin Invest"},{"key":"2020071613344987000_R84","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nm721","article-title":"Loss of HIF-2\u03b1 and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice","volume":"8","author":"Compernolle","year":"2002","journal-title":"Nat Med"},{"key":"2020071613344987000_R85","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0002-9149(98)00864-9","article-title":"Vascular endothelial growth factor in acute Kawasaki disease","volume":"83","author":"Terai","year":"1999","journal-title":"Am J Cardiol"},{"key":"2020071613344987000_R86","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00403-006-0641-9","article-title":"Increased production of vascular endothelial growth factor in the lesions of atopic dermatitis","volume":"297","author":"Zhang","year":"2006","journal-title":"Arch Dermatol Res"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/147\/11\/5400\/9030723\/endo5400.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/147\/11\/5400\/9030723\/endo5400.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T10:24:47Z","timestamp":1627727087000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/147\/11\/5400\/2500695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,1]]},"references-count":86,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2006-0657","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,1]]}}}